Kelonia Therapeutics Transforms from Struggles to a $3 Billion Valuation
The biotech sector sees notable developments as Kelonia Therapeutics rebounds significantly, while BioAge focuses on inflammation and other industry updates emerge.
Browse the full archive, newest first.